Abstract: A tarping system and method for covering at least a portion of a cargo load carried on a cargo carrying surface of a bed of a truck or trailer are provided. The tarping system includes at least one flexible tarp extending from a mounted end to a free end. At least one reel is coupled to the mounted end and is operative to automatically urge the tarp to a self-stowed positon, coiled onto a spool of the reel, under a return force imparted by the reel. A mounting structure is configured to support the at least one reel and the associated tarp in an upstanding relation relative to the cargo carrying surface to enable a user, while standing on the ground, to draw the tarp from the stowed position to a deployed position to cover at least a portion of a side of the cargo load.

Abstract: Apparatus for positioning a tarp on a payload carried on the bed of a vehicle includes a tarp lifting device having a carriage engagable with forks of a forklift truck and a support arm projecting from the carriage. Lifting hooks are provided on the support arm and engage anchor points of the tarp which is raised and drawn into position over the payload. Once placed, the support arm is lowered and the hooks drop free of the anchor points. The placement of the tarp occurs without an operator being on the bed or on top of the payload and the hooks disengage without assistance from the operator.

Abstract: An ice skate attachment assembly for converting a single runner blade ice skate into as multiple runner blade ice skate is provided. The assembly includes a skate guard having a bottom surface and including a channel for receiving and supporting the single runner blade of the ice skate. The assembly further includes at least two multi-runner blades secured with the skate guard and being laterally spaced from one another on either lateral side of the skate guard with each of the multi-runner blades extending below the bottom surface of the skate guard to an ice-engaging edge.

Abstract: An ice skate attachment assembly for converting a single runner blade ice skate into as multiple runner blade ice skate is provided. The assembly includes a skate guard having a bottom surface and including a channel for receiving and supporting the single runner blade of the ice skate. The assembly further includes at least two multi-runner blades secured with the skate guard and being laterally spaced from one another on either lateral side of the skate guard with each of the multi-runner blades extending below the bottom surface of the skate guard to an ice-engaging edge.

Abstract: An ice skate attachment assembly for converting a single runner blade ice skate into as multiple runner blade ice skate is provided. The assembly includes a skate guard having a bottom surface and including a channel for receiving and supporting the single runner blade of the ice skate. The assembly further includes at least two multi-runner blades secured with the skate guard and being laterally spaced from one another on either lateral side of the skate guard with each of the multi-runner blades extending below the bottom surface of the skate guard to an ice-engaging edge.

Abstract: The analgesic effectiveness of a combination drug containing at least one analgesic is significantly enhanced by the addition of a nontoxic N-methyl-D-aspartate (NMDA) receptor antagonist thereto.

Abstract: The analgesic effectiveness of a combination drug containing at least one analgesic is significantly enhanced by the addition of a nontoxic N-methyl-D-aspartate (NMDA) receptor antagonist thereto.

Abstract: The analgesic effectiveness of a combination drug composition containing at least one analgesic is significantly enhanced by the addition of a nontoxic N-methyl-D-aspartate (NMDA) receptor antagonist thereto.

Abstract: The analgesic effectiveness of an NSAID is significantly enhanced by administering the NSAID prior to, with or following the administration of an analgesia enhancer which is a nontoxic NMDA receptor blocker and/or a nontoxic substance that blocks at least one major intracellular consequence of NMDA receptor activation.

Abstract: Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA receptor activation, e.g., a ganglioside such as GM.sub.1 or GT.sub.1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl) -5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.

Abstract: Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA-receptor activation, e.g., a ganglioside such as GM.sub.1 or GT.sub.1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.

Abstract: A method of alleviating pain such as neuropathic pain or acute inflammatory pain is provided which comprises administering to a mammal that is either exhibiting pain or is about to be subjected to a pain-causing event a pain alleviating/pain suppressing amount of at least one nontoxic antagonist for the N-methyl-D-aspartate receptor, e.g., dextrorphan, or metabolic precursor of such antagonist, e.g., dextromethorphan, or at least one nontoxic substance that blocks a major intracellular consequence of N-methyl-D-aspartate receptor activation, e.g., a phenothiazine such as trifluoperazine.

Abstract: Chronic pain is alleviated in a mammal suffering therefrom by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, alone or in combination with a local anesthetic and optionally in sustained release dosage form.

Abstract: Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA receptor activation, e.g., a ganglioside such as GM.sub.1 or GT.sub.1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.

Abstract: Nontoxic substances that block the N-methyl-D-aspartate (NMDA) receptor, e.g., a morphinan such as dextromethorphan or dextrorphan, or that block a major intracellular consequence of NMDA-receptor activation, e.g., a ganglioside such as GM1 or GT1b, a phenothiazine such as trifluoperazine or a naphthalenesulfonamide such as N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, inhibit the development of tolerance to and/or dependence on addictive drugs, e.g., narcotic analgesics such as morphine, codeine, etc.